13F Holdings
中文EN

FLNA FILANA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1069530 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY60.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-60.5%
ROA-36.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets42.1%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.68x
Accruals ratio-11.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$26.59M$69.64M$89.42M$68.03M$24.81M
SG&A expense$68.80M$71.81M$16.53M$11.99M$8.05M
Operating income-$95.39M-$141.45M-$105.96M-$80.02M-$32.87M
Income tax$0$0———
Net income-$90.97M-$24.34M-$97.22M-$76.25M-$32.38M
EBITDA-$94.49M-$140.49M-$104.87M-$79.22M-$32.56M
EPS (basic)-1.88-0.53-2.32-1.90-0.82
EPS (diluted)-1.88-1.46-2.32-1.90-0.82
Weighted avg. shares (diluted)48.30M46.60M41.93M40.20M39.41M
Balance sheet
Cash & equivalents$95.50M$128.57M$121.14M$201.01M$233.44M
Current assets$97.71M$136.53M$129.63M$211.23M$244.48M
PP&E, net$20.65M$21.00M$21.85M$22.86M$20.62M
Intangibles$193,000$37,000$176,000$622,000$1.07M
Total assets$118.36M$157.53M$151.66M$234.83M$266.78M
Current liabilities$43.83M$11.75M$14.20M$7.06M$12.53M
Total liabilities$43.95M$11.83M$14.20M$7.29M$12.87M
Shareholders' equity$74.40M$145.70M$137.47M$227.54M$253.91M
Shares outstanding48.31M48.20M42.24M41.74M40.02M
Cash flow statement
Operating cash flow-$32.25M-$116.93M-$82.03M-$77.51M-$30.20M
Capital expenditure$581,000$103,000$414,000$2.71M$22.21M
Free cash flow-$32.83M-$117.03M-$82.44M-$80.23M-$52.41M
Investing cash flow-$581,000-$103,000-$414,000-$2.71M-$22.21M
Financing cash flow-$239,000$124.47M$2.56M$47.80M$192.34M
Depreciation & amortization$903,000$952,000$1.08M$804,000$310,000
Stock-based compensation$19.58M$16.29M$4.59M$2.07M$1.76M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.